Treadwell Therapeutics

Treadwell Therapeutics is a clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with highly aggressive cancers.

Treadwell Therapeutics is developing a novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity.

Treadwell Therapeutics was founded in 2019 and is headquartered in New York, New York.

 

Treadwell Therapeutics' robust, internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best-in-class TTK inhibitor, CFI-402257 ready for Phase 2, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1, which will enter the clinic in early 2020.

 

Treadwell Therapeutics has raised $27M in a Seed round on Jan 13, 2020. The financing is backed by TIO Bioventures.

 

 

  • Year founded: 2018
  • Funding Info: $27M over 1 Round (Funding Type: Seed- Series Unknown)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: New York
  • State: New York
  • Country: United States
Related businesses